Relatlimab/Nivolumab Improves PFS in Previously Untreated Metastatic or Unresectable Melanoma
Source: OncLive, March 2021
The fixed-dose combination of relatlimab plus nivolumab (Opdivo) was found to improve progression-free survival (PFS) over nivolumab alone in patients with previously untreated metastatic or unresectable melanoma, meeting the primary end point of the phase 2/3 RELATIVITY-047 (CA224-047; NCT03470922) trial.1
Relatlimab is an anti-LAG-3 antibody, and these phase 3 data are the first to be reported from a trial evaluating such an agent, according to Bristol Myers Squibb, the drug developer.
